DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

Allergan, Inc. (NYSE: AGN)



company name or ticker
Company Photos
(Click to zoom)

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Valeant Finally Bags Salix for $11 Billion

Ocular Therapeutix Eye-Pain Plug Flops Confirmatory Pivotal Trial

Can This Pharma Go From Good to Great?

Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?

Pershing Square Holdings: First Annual Report

Is It Time for GlaxoSmithKline plc to Change Management?

GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?

Merger Arbitrage Mondays - March 23, 2015

Why Pfizer Inc. Isn't Built to Last

Pfizer may be about to break up. Here's what investors need to know.

This Exciting Biotech Isn't Built to Last

Acadia Pharmaceuticals' Parkinson's disease drug was guaranteed a speedy review and the attention of top FDA officials. So why did this company's stock recently tank so rapidly? There's a cautionary tale here for all biotech investors.
See More Articles...